Antihypertensive medication use and change in kidney function in elderly adults: A marginal structural model analysis

International Journal of Biostatistics

Volumn 7, Issue 1, 2011, Pages

  Odden, Michelle C ^a   Tager, Ira B ^b   Van Der Laan, Mark J ^b   Delaney, Joseph A C ^c   Peralta, Carmen A ^b   Katz, Ronit ^d   Sarnak, Mark J ^e   Psaty, Bruce M ^d   Shlipak, Michael G ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

aged; hypertension; kidney function; marginal structural model

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ANALYTIC METHOD; ARTICLE; ELDERLY CARE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; BLOOD; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL;

AGED; ANTIHYPERTENSIVE AGENTS; CYSTATIN C; DATA INTERPRETATION, STATISTICAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL;

EID: 80053510654     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.2202/1557-4679.1320     Document Type: Article

References (37)

1. Arnold B, Arana B, Mausezahl D, Hubbard A, Colford JM, Jr. Evaluation of a pre-existing, 3-year household water treatment and handwashing intervention in rural Guatemala. Int J Epidemiol 2009; 38(6):1651-61.
2. Bembom O, Petersen ML, Rhee S, et al. Biomarker Discover Using Targeted Maximum Likelihood Estimation. Application to the Treatment of Antiretroviral Resistant HIV Infection. UC Berkeley Division of Biostatistics Working Paper Series 2007; Paper 221.
3. Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008;3(3):777-82.
4. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33 (Pubitemid 41773378)
5. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol 2002;155(11):1045-53. (Pubitemid 34587488)
6. Coresh J, Longenecker JC, Miller ER, 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S24-30.
7. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41(1):1-12. (Pubitemid 36043346)
8. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40(2):221-6. (Pubitemid 34827638)
9. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999;59(1):1-8. (Pubitemid 29133539)
10. Fewell Z, Hernan MA, Wolfe F, Tilling K, Choi H, Sterne JAC. Controlling for time-dependent confounding using marginal structural models. The Stata Journal 2004;4(4):402-420.
11. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997;43(6 Pt 1):1016-22. (Pubitemid 27246994)
12. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001;37(1):79-83. (Pubitemid 32055022)
13. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1(3):263-76.
14. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56(3):M146-56. (Pubitemid 32187141)
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305.
16. Gruber S, van der Laan M. Targeted Maximum Likelihood Estimation: A Gentle Introduction. UC Berkeley Division of Biostatistics Working Paper Series 2009; Paper 252.
17. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11(5):561-70. (Pubitemid 30660035)
18. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995;5(4):278-85.
19. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patientlevel data. Ann Intern Med 2001;135(2):73-87. (Pubitemid 32661190)
20. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334(1):13-8. (Pubitemid 26012498)
21. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877-84. (Pubitemid 24094966)
22. Levey AS, Mulrow CD. An editorial update: what level of blood pressure control in chronic kidney disease? Ann Intern Med 2005;143(1):79-81. (Pubitemid 40923338)
23. Mortimer KM, Neugebauer R, van der Laan M, Tager IB. An application of model-fitting procedures for marginal structural models. Am J Epidemiol 2005;162(4):382-8. (Pubitemid 41389720)
24. Neugebauer R, van der Laan MJ. Why Prefer Double Robust Estimates? Illustration with Causal Point Treatment Studies. J Stat Plan Infer 2005;129(1-2):405-426. (Pubitemid 39631036)
25. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol 1992;45(6):683-92.
26. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11(5):550-60. (Pubitemid 30660034)
27. Rosario RF, Wesson DE. Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 2006;15(2):130-4.
28. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939-46. (Pubitemid 41071427)
29. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142(5):342-51 (Pubitemid 40293407)
30. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352(20):2049-60. (Pubitemid 40664306)
31. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145(4):237-46. (Pubitemid 46768607)
32. Sinisi SE, van der Laan MJ. Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol 2004;3:Article18.
33. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin c alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51(3):395-406. (Pubitemid 351273480)
34. U.S. Renal Data Systems. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2008
35. van der Laan M, Rubin D. Targeted maxium likelihood learning. Int J Biostatistics 2006;2:Article 11.
36. Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31. (Pubitemid 35340538)
37. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002;13(11):2776-82. (Pubitemid 35216048)